Brain metastases in HER2-positive breast cancer: The evolving role of lapatinib

Institut Jules Bordet, Université Libre de Bruxelles, 121 Boulevard de Waterloo, 1000, Brussels, Belgium.
Critical reviews in oncology/hematology (Impact Factor: 4.03). 12/2009; 75(2):110-21. DOI: 10.1016/j.critrevonc.2009.11.003
Source: PubMed


Due to improvements in diagnosis and systemic therapy, brain metastases are an increasingly common cause of morbidity and mortality for patients with advanced breast cancer. The incidence of symptomatic brain metastases among women with metastatic breast cancer ranges from 10% to 16%. The HER2 receptor, which is overexpressed in approximately 25% of all breast cancers, is an important risk factor for the development of central nervous system metastases. Surgery and radiation therapy are the primary approaches to the treatment of brain metastases but new chemotherapy and biological agents promise to play an important role in the future management of central nervous system disease. This article reviews the epidemiology, current treatment options and recent advances in the field, with a focus on HER2-positive disease and the emerging role of lapatinib for the treatment and prevention of brain metastases.


Available from: Gianluca Tomasello, Sep 11, 2015
  • Source
    • "[32] Each treatment group had excellent local control (89% vs. 90%, P = 0.78) and required low rates of salvage WBRT (10 vs. 8%, P = 0.48, for 2-4 vs. 5-10 metastases, respectively). [30] Most series have documented an excellent rate of local control with the use of SRS alone [23,33] or in combination with WBRT. [34,20] In the recently published EORTC 22952 trial, SRS alone produced a local control rate greater than surgery alone with a local control rate at 1-year of 69% versus 41% for surgery, which improved to 81% when SRS was combined with WBRT. "
    [Show abstract] [Hide abstract] ABSTRACT: As local and systemic control of breast cancer improves, metastasis to the brain remains a common event requiring a specialized management approach. Women diagnosed with breast cancer who develop brain metastases have superior overall survival compared to patients with other forms of metastatic carcinoma. This article summarizes some of the unique aspects of care for patients with breast cancer metastases to the brain.
    Full-text · Article · Apr 2015 · Indian journal of medical and paediatric oncology
  • Source
    • "On the other hand, prevention from BM is important too. Many risk factors are associated with the development of BM, such as young age, hormone receptor-negative primary tumors, HER2+ tumors, and heavy burden of disease (large primary tumors, lymph node involvement, prior lung, liver, or bone metastases, increased number of metastatic sites, and elevated lactate dehydrogenase [LDH] levels) [1]. In breast cancer patients with high risk of brain metastasis, wholebrain irradiation may be studied in controlled clinical trials. "
    [Show abstract] [Hide abstract] ABSTRACT: Trastuzumab treatment does not prevent intracranial seeding and is largely ineffective for established central nervous system metastasis in HER2 overexpressing breast cancer patients. Combination therapy of lapatinib and capecitabine may be an effective treatment option for brain metastasis of HER2-positive breast cancer. We report a patient with breast cancer overexpressing HER-2 where brain metastases were successfully treated with radiation and a combination of lapatinib and capecitabine.
    Full-text · Article · Sep 2013 · Case Reports in Oncological Medicine
  • Source
    • "The median survival from first admission with brain metastases was only a few months, also in line with other studies (Lin and Winer, 2007; Tomasello et al, 2010). Breast cancer characteristics associated with more aggressive disease, ER and PR negativity and HER-2 overexpressing tumours (Gutierrez and Schiff, 2011; Stuckey, 2011) have been associated with an increased risk of brain metastases (Lin and Winer, 2007; Tomasello et al, 2010). Adjuvant anti-HER-2 antibody treatment, trastuzumab was introduced in 2000 and was gradually adopted in Sweden. "
    [Show abstract] [Hide abstract] ABSTRACT: While treatment for breast cancer has been refined and overall survival has improved, there is concern that the incidence of brain metastases has increased. We identified patients in Sweden with incident breast cancer 1998-2006 in the National Cancer Register, and matched these to the National Patient Register to obtain information on hospital admissions for distant metastases. Hazard ratios (HRs) and 95% confidence intervals (CIs) were computed with Cox regression as estimates of relative risk. Among 50 528 breast cancer patients, 696 (1.4%) were admitted with brain metastases during median 3.5 years of follow-up. Admissions for other metastases were found in 3470 (6.9%) patients. Compared with the period 1998-2000, patients diagnosed with breast cancer 2004-2006 were at a 44% increased risk of being admitted with brain metastases (HR 1.44, 95% CI 1.13-1.85). The incidence of admissions with brain metastases in breast cancer patients was increasing in the mid-2000s in Sweden. These findings support a true increase in incidence of brain metastases among breast cancer patients.
    Preview · Article · Apr 2012 · British Journal of Cancer
Show more